A Case Analyses of the Origin of Organizational Capability: Amgen Corporation’s Innovation Capabilities

• 발행기관: 한국외국어대학교 지식출판콘텐츠원 글로벌경영연구소
• 저자명: Chris Adalikwu Paul Adalikwu William Undie
• 간행물 정보: 『글로벌경영연구』제22권 제2호, 179~194쪽, 전체 16쪽
• 주제분류: 경제경영 > 경영학
• 파일형태: PDF
• 발행일자: 2010.08.30

영문 초록

To strategy scholars and managers, the origin of organizational capabilities is elusive. A scholar wonders “where [do] capabilities come from [and] what kinds of investment in money, time, and managerial efforts is required in building them” Ethiraj, et al. (2005, Strategic Management Journal, 26, 25-45). This study traced the trajectory of strategic asset deployment by Amgen’s top echelon to capture the origin of Amgen’s drug innovation capabilities. Sequentially, Amgen’s top echelon strategically acquired star scientists, who in turn, developed Amgen’s drug innovation capabilities. This finding is consistent with the upper-echelon and resource-based theories about the strategic roles of top managers in developing organizational capabilities. We hope, managers should learn from this insightful case.

목차

Ⅰ. Background

Ⅱ. Organizational Capabilities Linked to Inter-organizational Performance Differences

Ⅲ. Upper-Echelon Theory: The Beginning of the Origin of Organizational Capabilities

Ⅳ. Innovation Capabilities and Investors’ Perception of Value in the Firm

Ⅴ. Conclusion and Recommendations

References